FAAH and metabolic dysfunction-associated steatohepatitis: FAAH deficiency also promotes insulin resistance and liver steatogenesis, two key steps in the pathogenesis of non-alcoholic fatty liver disease, and CB1 antagonists have been proposed in the management of NASH [42].